Dataset Information


Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.

ABSTRACT: The pathogenesis of orbital Graves' disease (GD), a process known as thyroid-associated ophthalmopathy (TAO), remains incompletely understood. The thyrotropin receptor (TSHR) represents the central autoantigen involved in GD and has been proposed as the thyroid antigen shared with the orbit that could explain the infiltration of immune cells into tissues surrounding the eye. Another cell surface protein, insulin-like growth factor-I receptor (IGF-IR), has recently been proposed as a second antigen that participates in TAO by virtue of its interactions with anti-IGF-IR antibodies generated in GD, its apparent physical and functional complex formation with TSHR, and its necessary involvement in TSHR post-receptor signaling. The proposal that IGF-IR is involved in TAO has provoked substantial debate. Furthermore, several studies from different laboratory groups, each using different experimental models, have yielded conflicting results. In this article, we attempt to summarize the biological characteristics of IGF-IR and TSHR. We also review the evidence supporting and refuting the postulate that IGF-IR is a self-antigen in GD and that it plays a potentially important role in TAO. The putative involvement of IGF-IR in disease pathogenesis carries substantial clinical implications. Specifically, blocking this receptor with monoclonal antibodies can dramatically attenuate the induction by TSH and pathogenic antibodies generated in GD of proinflammatory genes in cultured orbital fibroblasts and fibrocytes. These cell types appear critical to the development of TAO. These observations have led to the conduct of a now-completed multicenter therapeutic trial of a fully human monoclonal anti-IGF-IR blocking antibody in moderate to severe, active TAO.


PROVIDER: S-EPMC5206614 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5718165 | BioStudies
2015-01-01 | S-EPMC4687015 | BioStudies
2014-01-01 | S-EPMC3968932 | BioStudies
2013-01-01 | S-EPMC3783445 | BioStudies
1000-01-01 | S-EPMC3339887 | BioStudies
2014-01-01 | S-EPMC4154099 | BioStudies
2018-01-01 | S-EPMC6070359 | BioStudies
2015-01-01 | S-EPMC4655214 | BioStudies
2011-01-01 | S-EPMC3048317 | BioStudies
2019-01-01 | S-EPMC6657650 | BioStudies